Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Gardiner

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Iscience|May 10, 2024
Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancerAnne Knisely, Emily M Hinchcliff, Elisabeth Gardiner, et al.
Molecular Cell|October 7, 2014
Oxidative stress diverts tRNA synthetase to nucleus for protection against DNA damageNa Wei, Yi Shi, Lan N Truong, et al.
Science (New York, N.Y.)|July 19, 2014
Human tRNA synthetase catalytic nulls with diverse functionsWing-Sze Lo, Elisabeth Gardiner, Zhiwen Xu, et al.
Journal of Medicinal Chemistry|January 24, 2024
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene AlterationsJohn S Tyhonas, Lee D Arnold, Jason M Cox, et al.
Journal of Medicinal Chemistry|January 17, 2024
The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase InhibitionYoung K Chen, Toufike Kanouni, Lee D Arnold, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Iscience|May 10, 2024
Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancerAnne Knisely, Emily M Hinchcliff, Elisabeth Gardiner, et al.
Molecular Cell|October 7, 2014
Oxidative stress diverts tRNA synthetase to nucleus for protection against DNA damageNa Wei, Yi Shi, Lan N Truong, et al.
Science (New York, N.Y.)|July 19, 2014
Human tRNA synthetase catalytic nulls with diverse functionsWing-Sze Lo, Elisabeth Gardiner, Zhiwen Xu, et al.
Journal of Medicinal Chemistry|January 24, 2024
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene AlterationsJohn S Tyhonas, Lee D Arnold, Jason M Cox, et al.
Journal of Medicinal Chemistry|January 17, 2024
The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase InhibitionYoung K Chen, Toufike Kanouni, Lee D Arnold, et al.
Pageof 1